Therapeutic vaccination using minimal HPV16 epitopes in a novel MHC-humanized murine HPV tumor model

ABSTRACT Therapeutic vaccination as a treatment option for HPV-induced cancers is actively pursued because the two HPV proteins E6 and E7 represent ideal targets for immunotherapy, as they are non-self and expressed in all tumor stages. MHC-humanized mice are valuable tools for the study of therapeutic cancer vaccines – given the availability of a suitable tumor model. Here, we present for the first time an HPV16 tumor model suitable for fully MHC-humanized A2.DR1 mice, PAP-A2 cells, which in contrast to existing HPV16 tumor models allows the exclusive study of HLA-A2- and DR1-mediated immune responses, without any interfering murine MHC-presented epitopes. We used several HPV16 epitopes that were shown to be presented on human cervical cancer cells by mass spectrometry for therapeutic anti-tumor vaccination in the new tumor model. All epitopes were immunogenic when rendered amphiphilic by incorporation into a molecule containing stearic acids. Prophylactic and therapeutic vaccination experiments with the epitope E7/11–19 demonstrated that effective immune responses could be induced with these vaccination approaches in A2.DR1 mice. Interestingly, the combination of E7/11–19 with other immunogenic HPV16 E6/E7 epitopes caused a reduction of vaccine efficacy, although all tested combinations resulted in a survival benefit. In summary, we present the first HPV16 tumor model for exclusive studies of HLA-A2-mediated anti-HPV tumor immune responses and show anti-tumor efficacy of minimal epitope vaccines.

[1]  C. Slingluff,et al.  Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide , 2013, Cancer Immunology, Immunotherapy.

[2]  K. Smith-McCune,et al.  Evolving immunosuppressive microenvironment during human cervical carcinogenesis , 2008, Mucosal Immunology.

[3]  V. Engelhard,et al.  Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy , 2018, The Journal of clinical investigation.

[4]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[5]  A. Riemer,et al.  The Invisible Enemy – How Human Papillomaviruses Avoid Recognition and Clearance by the Host Immune System , 2012, The open virology journal.

[6]  B. Ni,et al.  Cytolytic Activity of the Human Papillomavirus Type 16 E711-20 Epitope-Specific Cytotoxic T Lymphocyte Is Enhanced by Heat Shock Protein 110 in HLA-A*0201 Transgenic Mice , 2013, Clinical and Vaccine Immunology.

[7]  S. Stokley,et al.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2019 , 2020, MMWR. Morbidity and mortality weekly report.

[8]  C. Benoist,et al.  Mice lacking all conventional MHC class II genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[9]  T. Wu,et al.  Characterization of HLA-A2-restricted HPV-16 E7-specific CD8+ T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice , 2006, Gene Therapy.

[10]  A. Riemer,et al.  Immune evasion mechanisms of human papillomavirus: An update , 2018, International journal of cancer.

[11]  A. Ribas,et al.  Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.

[12]  K. Barrios,et al.  BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses , 2013, Cancer Immunology, Immunotherapy.

[13]  Mengyu Wang,et al.  Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model , 2017, Oncoimmunology.

[14]  Sarah A. Meyer,et al.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2016 , 2017, MMWR. Morbidity and mortality weekly report.

[15]  Ryan L. Kelly,et al.  Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses , 2016, Nature Medicine.

[16]  Chien-Fu Hung,et al.  Development of a DNA Vaccine Targeting Human Papillomavirus Type 16 Oncoprotein E6 , 2004, Journal of Virology.

[17]  Edgar G. Engleman,et al.  Allogeneic IgG combined with dendritic cell stimuli induces anti-tumor T cell immunity , 2015, Nature.

[18]  M. Rice,et al.  Preterm neonatal morbidity and mortality by gestational age: a contemporary cohort. , 2016, American journal of obstetrics and gynecology.

[19]  D. Lowy,et al.  Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment , 2016, American journal of obstetrics and gynecology.

[20]  H. Rammensee,et al.  Identification of Immunogenic Epitopes by MS/MS , 2017, Cancer journal.

[21]  The role of human papillomaviruses in human cancers. , 2002 .

[22]  M. Mansour,et al.  Rejection of large HPV-16 expressing tumors in aged mice by a single immunization of VacciMax® encapsulated CTL/T helper peptides , 2007, Journal of Translational Medicine.

[23]  S. Stevanović,et al.  A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function. , 2010, Journal of immunological methods.

[24]  S. Stokley,et al.  National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2014 , 2015, MMWR. Morbidity and mortality weekly report.

[25]  Nicolas Wentzensen,et al.  Carcinogenic human papillomavirus infection , 2016, Nature Reviews Disease Primers.

[26]  V. Engelhard,et al.  Importance of MHC class 1 alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules. , 1996, Journal of immunology.

[27]  S. Kanodia,et al.  Mechanisms used by human papillomaviruses to escape the host immune response. , 2007, Current cancer drug targets.

[28]  Larry R. Smith,et al.  Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. , 2002, Cancer research.

[29]  A. Riemer,et al.  Therapeutic Vaccine Strategies against Human Papillomavirus , 2014, Vaccines.

[30]  C. Liu,et al.  Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.

[31]  R. Madan,et al.  Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors , 2016, Expert opinion on biological therapy.

[32]  S. Pascolo.  HLA class I transgenic mice: development, utilisation and improvement , 2005, Expert opinion on biological therapy.

[33]  Martin R Larsen,et al.  A Targeted LC‐MS Strategy for Low‐Abundant HLA Class‐I‐Presented Peptide Detection Identifies Novel Human Papillomavirus T‐Cell Epitopes , 2018, Proteomics.

[34]  F. Bray,et al.  Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. , 2016, The Lancet. Global health.

[35]  M. Plummer,et al.  Worldwide burden of cancer attributable to HPV by site, country and HPV type , 2017, International journal of cancer.

[36]  M. von Knebel Doeberitz,et al.  ERAP1 overexpression in HPV-induced malignancies: A possible novel immune evasion mechanism , 2017, Oncoimmunology.

[37]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[38]  E. Rybicki,et al.  Therapeutic vaccines for high-risk HPV-associated diseases , 2017, Papillomavirus research.

[39]  A. Pajot,et al.  A mouse model of human adaptive immune functions: HLA‐A2.1‐/HLA‐DR1‐transgenic H‐2 class I‐/class II‐knockout mice , 2004, European journal of immunology.

[40]  T. Kirby.  FDA approves new upgraded Gardasil 9. , 2015, The Lancet. Oncology.

[41]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[42]  S. Stevanović,et al.  A vaccine targeting mutant IDH1 induces antitumour immunity , 2014, Nature.

[43]  R. Rees,et al.  HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides , 2007, Cancer Immunology, Immunotherapy.